Certara, Inc.
CERTHealthcareNASDAQHealth Information Services · Last scanned Jul 16, 2026
Scan Results
Daily timeframePart of the healthcare sector, Certara, Inc. (CERT) is listed under Health Information Services. The company carries a $1.10B market cap, placing it firmly in the small-cap category. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes.
Market Cap
$1.10B
Beta
1.46
P/E (TTM)
—
P/E (Fwd)
17.06
EPS (TTM)
$-0.11
EPS (Fwd)
$0.41
ROE
-1.4%
ROA
0.8%
Cash
$149.5M
Total Debt
$304.7M
Free CF
$116.6M
52W Change
-32.2%
Annual Financials
Cash vs Debt
On the balance sheet, CERT has $149.5M in cash with $304.7M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Annual free cash flow of $116.6M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at -1.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 0.8% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $335.6M (2022) to $418.8M (2025), reflecting a 25% increase over the period.
As with any equity investment, CERT carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing CERT.